PAOG PAO GROUP INC

PAOG 2021 CBD Nutraceuticals Rollout Preview This Friday

Sandusky, Ohio--(Newsfile Corp. - May 5, 2021) - PAO Group, Inc. (OTC Pink: PAOG) today confirmed a CBD Nutraceutical Sales Rollout Presentation scheduled this Friday, May 7, 2021.

Last year, PAOG acquired RespRx from Kali-Extracts, Inc. (OTC Pink: KALY). RespRx is a CBD treatment under development for Chronic Obstructive Pulmonary Disorder (COPD) derived from a patented cannabis extraction method - U.S. Patent No. 9,199,960 entitled "METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT."

PAOG is working with, a contract research organization (CRO), dedicated to the clinical advance of therapies and treatments through regulatory approval.

Separately, PAOG is working with Alkame Holdings, Inc. (OTC Pink: ALKM) and North American Cannabis Holdings, Inc. (OTC Pink: USMJ) on packaging and marketing that draws on PAOG's cannabis extract intellectual property to produce a line of CBD Nutraceuticals for a broad spectrum of consumers' interests in a healthy lifestyle.

Learn more about PAOG at .

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

CONTACT INFORMATION

Contact Us:
Jim DiPrima
888-272-6472

To view the source version of this press release, please visit

EN
05/05/2021

Underlying

PAOGPAO GROUP INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PAO GROUP INC

 PRESS RELEASE
Free
PAOG PAO GROUP INC

PAOG Expects Increased Visibility For Its CBD Nutraceuticals From USMJ...

PAOG Expects Increased Visibility For Its CBD Nutraceuticals From USMJ Ecommerce Campaign Sandusky, OH, Feb. 03, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced the company expects to enjoy increased market visibility for its RX Branded CBD Nutraceuticals resulting from the announced earlier today. PAOG currently markets its own independent line of CBD nutraceutical products under its “RX” label available for sale on North American Cannabis Inc.’s (OTC Pink: USMJ) ecommerce site . PAOG is also working with Puration, Inc. (OTC Pink: PURA) on the develop...

February 3, 2022 1 EN
 PRESS RELEASE
Free
PAOG PAO GROUP INC

PAOG To Expand CBD Nutraceutical Sales In 2022 And Continue Pharmaceut...

PAOG To Expand CBD Nutraceutical Sales In 2022 And Continue Pharmaceuticals Development Sandusky, OH, Feb. 01, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today republished its 2022 strategic update on the company’s CBD pharmaceutical and nutraceutical development strategy.  The update was originally released on Friday, January 27th, 2022. The update is included in its entirety below: PAO Group, Inc. is an emerging cannabis and CBD company targeting growth via two tracks – pharmaceutical and nutraceutical. The Company is developing a cannabis extract-based therapy to tre...

February 1, 2022 1 EN
 PRESS RELEASE
Free
PAOG PAO GROUP INC

PAOG Publishes 2022 Strategic Update

PAOG Publishes 2022 Strategic Update Sandusky, OH, Jan. 28, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today released a 2022 strategic update on the company’s CBD pharmaceutical and nutraceutical development strategy. The update is included in its entirety below: PAO Group, Inc. is an emerging cannabis and CBD company targeting growth via two tracks – pharmaceutical and nutraceutical. The Company is developing a cannabis extract-based therapy to treat various respiratory diseases and illnesses including COPD.  Recent independent has confirmed PAOG’s previous conclusion...

January 28, 2022 1 EN
 PRESS RELEASE
Free
PAOG PAO GROUP INC

PAOG Cites Research On Hemp Compounds Effectiveness Treating Covid To ...

PAOG Cites Research On Hemp Compounds Effectiveness Treating Covid To Advance Pharmaceutical Development Sandusky, OH, Jan. 25, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today cited recently published information on research indicating CBDA and CBGA, compounds found in hemp, “block a critical step in the process the [Covid] virus uses to infect people” (). “The two compounds were identified during a chemical screening by researchers at the Linus Pauling Institute at Oregon State University. The compounds bind to spike proteins found on the virus and blocked the spike ...

January 25, 2022 1 EN
 PRESS RELEASE
Free
PAOG PAO GROUP INC

PAOG Confirms Farmersville Hemp Brand CBD Product Line Development For...

PAOG Confirms Farmersville Hemp Brand CBD Product Line Development For PURA Sandusky, OH, Jan. 06, 2022 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today confirmed the development of a line of CBD nutraceutical products for Puration, Inc. (OTC Pink: PURA) is underway. PURA has updated its business model over the course of the last year and is now focusing on the development of a hemp business cooperative under the brand name Farmersville Hemp.  PURA has established its new business model to build an industrial hemp business with 3 sources of revenue – education, brandi...

January 6, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch